Become a Member
  • Track your favourite stocks
  • Create & monitor portfolios
  • Daily portfolio value
Sign Up
Quickpicks
Add shares to your
quickpicks to
display them here!

IN BRIEF: Omega Diagnostics awaits approval for home use of Visitect

6th Sep 2021 12:39

Omega Diagnostics Group PLC - medical diagnostics company - Says all of the supporting data and documentation relating to its submission for CE marking for self-test use for the Visitect Covid-19 antigen test have been filed. The submission process has been running in parallel with the usability study conducted by Ulster University since mid-July and the conclusion of the Ulster study was the final step in this process. The test is already CE marked for professional-use and once approved would allow the test to be sold in Europe for home-use as well.

Current stock price: 53.56 pence

Year-to-date change: down 17%

By Evelina Grecenko; [email protected]

Copyright 2021 Alliance News Limited. All Rights Reserved.


Related Shares:

ODX.L
FTSE 100 Latest
Value8,809.74
Change53.53